Can type 1 diabetes be prevented?
Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
Everything else on this site about prevention has a list of things that work. This page does not, and saying so clearly matters more than finding something optimistic to recommend.
What does exist is real and recent: the disease can be detected years early, and its onset can be delayed. That is not prevention, and it is a long way from nothing.
Related pages: Type 1 diabetes
The bottom line
- No diet, supplement or lifestyle change prevents type 1 diabetes.
- Nothing a parent did or did not do causes it.
- Antibody screening identifies the disease years before symptoms.
- Teplizumab delays clinical onset in people at stage 2.
- Beta-cell replacement research is progressing but is limited by immunosuppression.
- What triggers the autoimmune process.
- Whether combination immune therapy will achieve prevention.
- Whether stem-cell-derived islets can work without immunosuppression.
The story, step by step
What the evidence labels mean
The trials that were run
What happens
A long list of honest failures.
What the research shows
- Oral and nasal insulin, given to induce immune tolerance in at-risk relatives, did not prevent the disease in large trials.
- Nicotinamide was tested on a large scale and did not work.
- Hydrolysed infant formula, tested on the hypothesis that early cow's milk protein exposure triggers the process, did not reduce risk in a long randomised trial.
- Vitamin D supplementation, omega-3 fatty acids and gluten-free diets in infancy have not been shown to prevent it.
- Avoiding sugar has no effect, because sugar intake has nothing to do with the cause.
- These were serious, well-designed trials. The failures are informative, and they are the reason the field moved toward intervening later, once the process has started.
Why it matters
The repeated negative results are themselves evidence worth stating, because they are what makes confident claims elsewhere so implausible.
What's still uncertain
- Whether earlier intervention in infancy could still work.
- What the failures reveal about the mechanism.
Read more
- NIH: TrialNet and type 1 diabetes prevention researchGovernment
- NIDDK: Type 1 diabetesGovernment
- American Diabetes Association: standards of care resourcesNonprofit
Next: What does work
Detection and delay
What happens
Not prevention, but real.
What the research shows
- Islet autoantibody screening identifies people in the presymptomatic stages, years before symptoms.
- Screening programmes exist for relatives, and population screening is being studied in several countries.
- Knowing substantially reduces the chance of presenting in ketoacidosis, which is both dangerous and common at first diagnosis.
- Teplizumab, licensed in the United States for people aged 8 and over with stage 2 disease, delays clinical onset by a median of around two years.
- Other immune therapies are in trials, including drugs used in rheumatology, and combination approaches are being tested.
- Trials also now test therapies immediately after diagnosis, aiming to preserve the beta cells that remain rather than prevent the disease.
Why it matters
The shift from preventing the disease to delaying it and preserving function is the single most important change in this field in decades.
What's still uncertain
- How long the delay from teplizumab lasts.
- Whether combination therapy will do better.
Read more
- NIH: TrialNet and type 1 diabetes prevention researchGovernment
- FDA: drug and device informationGovernment
- American Diabetes Association: standards of care resourcesNonprofit
Next: What people are told
Claims that cause harm
What happens
Worth addressing directly.
What the research shows
- Type 1 diabetes cannot be reversed by diet, fasting, supplements, herbs or any alternative protocol. Claims otherwise are false.
- These claims cause specific, documented harm: people reduce or stop insulin, develop ketoacidosis, and children have died.
- The honeymoon phase is often what such claims are built on. Insulin needs genuinely fall for months after diagnosis, and any intervention started then appears to work.
- Type 2 diabetes remission with weight loss is real, and the two conditions get conflated, which is where much of the confusion comes from.
- Vaccines do not cause type 1 diabetes, and this has been examined repeatedly in large population studies.
- If someone wants to try something unproven, the one non-negotiable is that insulin continues. Anything that requires reducing insulin is dangerous.
Why it matters
This is the one area where a page about prevention has to be blunt, because the alternative claims here are not merely useless.
What's still uncertain
- How to counter these claims effectively.
- How often insulin reduction follows alternative advice.
Read more
- NIDDK: Type 1 diabetesGovernment
- CDC: Type 1 diabetesGovernment
- American Diabetes Association: standards of care resourcesNonprofit
Next: The horizon
Replacement and cure research
What happens
Genuine progress, real constraints.
What the research shows
- Islet transplantation, using donor cells, can produce insulin independence but requires lifelong immunosuppression and is limited by donor supply, so it is reserved for specific situations.
- Stem-cell-derived beta cells have produced insulin independence in early trials, which removes the donor supply problem.
- The remaining obstacle is immune protection: the transplanted cells face both the original autoimmunity and standard rejection.
- Approaches under investigation include encapsulation devices, gene editing to make cells immune-evasive, and targeted immune tolerance.
- Automated insulin delivery is improving in parallel, and for most people it will be the practical answer for years to come.
- Research is funded substantially by patient-founded organisations, which is unusual and is one reason the field moves as it does.
Why it matters
A functional cure now looks plausible rather than hypothetical, which is a genuine change, while remaining some distance from routine availability.
What's still uncertain
- Whether encapsulation can avoid immunosuppression.
- How long until stem-cell therapy is widely available.
Read more
- NIH: TrialNet and type 1 diabetes prevention researchGovernment
- Breakthrough T1D (formerly JDRF)Nonprofit
- NIDDK: Type 1 diabetesGovernment